Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Study to Assess the Safety and Tolerability of Single and Multiple Ascending Doses of Oral RO7020531 in Chinese Healthy Participants.
- First Posted Date
- 2018-05-21
- Last Posted Date
- 2020-07-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 70
- Registration Number
- NCT03530917
- Locations
- 🇭🇰
Prince of Wales Hospital, Shatin, New Territories, Hong Kong
A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2018-05-14
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 927
- Registration Number
- NCT03523858
- Locations
- 🇺🇸
Cleveland Clinic Mellen Center; U10, Cleveland, Ohio, United States
🇺🇸University of Cincinnati; Department of Neurology, Cincinnati, Ohio, United States
🇺🇸Lone Star Neurology of San Antonio, San Antonio, Texas, United States
Open Label, Adaptive, Parallel Group PET Study Using RO7017773 And [11C] RO15-4513
- Conditions
- Interventions
- First Posted Date
- 2018-04-25
- Last Posted Date
- 2019-09-30
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 6
- Registration Number
- NCT03507569
- Locations
- 🇬🇧
Hammersmith Medicines Research; Central Middlesex Hospital, London, United Kingdom
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of RO7062931 in Healthy Chinese Volunteers.
- First Posted Date
- 2018-04-23
- Last Posted Date
- 2020-08-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 41
- Registration Number
- NCT03505190
- Locations
- 🇭🇰
Queen Mary Hospital, Hong Kong, Hong Kong
🇭🇰Prince of Wales Hospital, Shatin, New Territories, Hong Kong
A Study of Balovaptan in Adults With Autism Spectrum Disorder With a 2-Year Open-Label Extension
- First Posted Date
- 2018-04-20
- Last Posted Date
- 2021-10-27
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 322
- Registration Number
- NCT03504917
- Locations
- 🇺🇸
Woodland Research Northwest, LLC, Rogers, Arkansas, United States
🇺🇸MCB Clinical Research Centers, Colorado Springs, Colorado, United States
🇺🇸Millennium Psychiatric Associates, LLC, Saint Louis, Missouri, United States
A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-04-17
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 2199
- Registration Number
- NCT03498716
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States
🇦🇺Royal Adelaide Hospital; Cancer Centre, Adelaide, South Australia, Australia
A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site
- Conditions
- Interventions
- Drug: AlectinibDrug: VismodegibDrug: IpatasertibDrug: CarboplatinDrug: OlaparibDrug: ErlotinibDrug: CisplatinDrug: BevacizumabDrug: GemcitabineDrug: VemurafenibDrug: CobimetinibDrug: Trastuzumab Subcutaneous (SC)Drug: PertuzumabDrug: AtezolizumabDrug: PaclitaxelDrug: EntrectinibDrug: IvosidenibDrug: Pemigatinib
- First Posted Date
- 2018-04-13
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 528
- Registration Number
- NCT03498521
- Locations
- 🇦🇺
Northern Cancer Institute, St Leonards, New South Wales, Australia
🇦🇺Blacktown Hospital, Blacktown, New South Wales, Australia
🇫🇮Helsinki University Central Hospital; Dept of Oncology, Helsinki, Finland
A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-04-11
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 500
- Registration Number
- NCT03493854
- Locations
- 🇨🇦
The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada
🇯🇵St. Luke's International Hospital, Tokyo, Japan
🇧🇪Institut Jules Bordet, Anderlecht, Belgium
An Open-Label Crenezumab Study in Participants With Alzheimer's Disease
- First Posted Date
- 2018-04-09
- Last Posted Date
- 2020-07-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 149
- Registration Number
- NCT03491150
- Locations
- 🇺🇸
Anderson Clinical Research, Inc., Redlands, California, United States
🇺🇸University of California, Davis; Alzheimers Disease Center, Department of Neurology, Sacramento, California, United States
🇫🇷Hopital La Grave; Place Lange, Toulouse Cedec, France
Participant-Reported Outcomes With the Accu-Chek® Solo Micropump System
- Conditions
- Interventions
- First Posted Date
- 2018-03-27
- Last Posted Date
- 2021-08-20
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 181
- Registration Number
- NCT03478969
- Locations
- 🇦🇹
Hietzing Hospital, Vienna, Austria
🇩🇪Diabetes Klinik Bad Mergentheim GmbH, Bad Mergentheim, Germany
🇩🇪InnoDiab Forschung GmbH, Essen, Germany